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The word persistence was used by Chlamydia researchers almost as soon as Chlamydia
research was born to reflect the propensity of chlamydiae to cause inapparent infection
in their hosts, from birds to humans. More recently, the term persistence has been used,
misused, and sometimes abused amidst in vitro and in vivo studies that aim to mimick
the ability of chlamydiae to emerge from the presumed inapparent state into clinically
detectable infection and disease. Here, I have attempted to provide a global perspective
on the state of research on chlamydial persistence, revisiting old observations that may
warrant a new look, critically evaluating more recent observations and their shortcomings,
and including recent developments that may help redefine chlamydiae as pathogens—or
not—of both animals and humans.
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“Essentially, all models are wrong, but some are useful” (George E.
P. Box).
The word persistence derives from the Latin persistere where
per conveys the notion of permanence while the verb sistere is
most frequently translated as to stand still. Thus, the question
before us is whether the word persistence is appropriately used
to describe chlamydiae that are able to “stand still permanently”
in a susceptible host.
Bacterial persistence in plain English has been described often
and in many different contexts. A compendium of these descrip-
tions may be summarized as follows: Persistence is an alternative
outcome of a bacterial infection whereby a subpopulation of
the bacteria becomes “invisible” by variably escaping prolonged
antibiotic treatment, warding off innate and adaptive immune
responses, causing little or no symptoms in the infected host,
and falling below the radar of the diagnostician. Cryptic, latent,
covert, dormant, or silent are other terms that have been com-
monly used to refer to the “persistent” infection state which may
consist of an altered form of the bacterium that is inherently phys-
iologically refractory to all the above, or a normal form of the
bacterium that is somehow hidden and/or effectively protected
from all the above. If one takes away the notion of infection from
these definitions, then a persistent, asymptomatic infection may
closely resemble colonization, similar to that by a member of the
microbiota, i.e., a commensal organism. Where do Chlamydia
spp. Belong on the spectrum of commensalism and pathogene-
sis, and how this impacts the terminology that should be used to
refer to persistence are the subject of this commentary.
From a public health point of view, the ability of Chlamydia
trachomatis to persist is made significant by its ability to occur
or recur as an acute infection since persistence on its own would
be of little medical interest. In a formal sense, two basic, non-
mutually exclusive scenarios should be considered: (1) a clinically
detectable infection may recur from a persistent state interven-
ing between two acute episodes; (2) alternatively, a clinically
detectable infection may be induced “opportunistically” from a
silent state, whereby the host has been colonized or infected at an
earlier date without any symptoms or clinical signs of infection.
Here, I will respectively refer to these pathways as the persis-
tence/recurrence and colonization pathways. In either case, the
previously “invisible” C. trachomatis population becomes “vis-
ible” to the host cell, the infected host or to the physician.
However, although a distinction between these two scenarios
is not usually made, they likely are biologically distinct in the
manner chlamydiae become established in the host, how they
exit from the “invisible” state, and also in the innate and adap-
tive responses they elicit, and consequent pathologies. In the
absence of evidence for the colonization pathway for C. tra-
chomatis to date, far more attention has been given to the persis-
tence/recurrence mechanism owing principally to the emergence
in the last two decades of several related in vitromodels (reviewed
in Wyrick, 2010) that recapitulated the basic requirements of
the persistence/recurrence phenotype: the induction of infecting
chlamydiae into developmental arrest upon exposure to a physio-
logically relevant stimulus (mimicking in vivo persistence), and
the subsequent reversal to normal development upon removal
of the stimulus (mimicking in vivo recurrence) in cultured cells.
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However, the concept of persistence did not start with human
C. trachomatis infections; it started with the avian pathogen,
Chlamydia psittaci.
The concept of latent chlamydial infection was born in the
1930s from observations by Meyer and Eddie who contrasted
the frequent occurrence of the psittacosis virus, known today
as C. psittaci, in companion birds with the relative rarity of
overt disease in the birds themselves or the bird handlers (Meyer
et al., 1935). Thus, the idea of persistent infection was borne
out of the observation that multiple hosts may display com-
pletely different outcomes after exposure to the organism, with
the majority displaying a latent infection, and a minority dis-
playing overt disease. For infection to recur, it needs to have
occurred at least once previously, and it is unclear from these
studies whether the latent infected birds had a clinically detectable
infection at the onset or were merely colonized. Decades after
these early observations, several investigators were able to demon-
strate that chlamydial development could be arrested at mid
stage by either depriving the chlamydiae of essential metabo-
lites (Bader and Morgan, 1961; Hatch, 1975) or via exposure
to aminopterin (Pollard and Sharon, 1963), a folic acid com-
petitive inhibitor and antineoplastic drug once commonly used
in chemotherapy. Restitution of the required nutrients, or, in
the latter case, supplementation with folinic acid, a vitamer of
folate, restored the normal course of development, thereby ful-
filling the essential requirements of the persistence/recurrence
phenotype. These pioneering studies involved latent infection by
C. psittaci and a link was not made then with other chlamydial
diseases.
Moulder and his colleagues were the first to tackle the ques-
tion of persistent/recurrent infection in a systematic experimen-
tal manner and were, indeed, first to develop in vitro models
of persistence presumed to represent clinically observed persis-
tence in several seminal publications. When mouse fibroblasts
(L cells) were infected with high doses of C. psittaci 6BC, most
L cells died but a small fraction survived that appeared to be
persistently infected with C. psittaci, yet were inclusion-free by
standard imaging methods of the time (Moulder et al., 1980).
The cryptically infected L cells grew poorly, became resistant to
super-infection (Moulder et al., 1981, 1982) and the cultures
alternated between L cell expansion and chlamydial growth. A
subpopulation of L cells with unique properties that enabled per-
sistent infection by cryptic forms of C. psittaci was hypothesized.
McCoy cell cultures persistently infected with a non-LGV strain
of C. trachomatis were also obtained upon generating an equi-
librium whereby periods of host cell propagation alternated with
chlamydial growth and host cell destruction (Lee and Moulder,
1981). While Moulder and colleagues did not have the bene-
fit of PCR, modern omics or imaging techniques, their studies
described the ability of chlamydiae to maintain themselves in cul-
ture for extended periods of time, representative of a presumed
“persistent state” in clinical disease, and to revert upon some
unknown stimulus representative of recurrence. Unfortunately,
these studies were discontinued around the eighties. Moulder did
one last experiment on cryptic bodies that was a precursor of
the next era of studies on chlamydial persistence/recurrence. He
observed that he could delay the onset of overt chlamydial growth
by shifting C. psittaci-persistently infected L cells to a nutrient-
poor minimal medium or upon exposure to penicillin (Moulder,
1983).
A student of Moulder, Byrne, and his colleagues took the mod-
eling of persistence/recurrence to a new level when they repro-
duced inducible persistence/recurrence in cultured cells using a
physiologically relevant stimulus. Beatty et al. (1993) showed that
in the presence of low levels of the cytokine interferon-gamma
(IFN-γ), developmental growth of C. trachomatis serovar A
stopped, producing large atypical reticulate body (RB) forms and
that reversion to productive development to infectious elemen-
tary bodies (EBs) could be rescued by removal of the cytokine.
IFN-γ was shown to exert its activity through tryptophan deple-
tion upon induction of the tryptophan catabolizing enzyme
indoleamine 2,3-dioxygenase (IDO) (Beatty et al., 1994), funda-
mentally reducing this mechanism to starvation for an essential
nutrient. Similar results, including the observation of abnormally
large RBs, consistent with persistence/recurrence were concur-
rently obtained by Pearce and his colleagues who tested the
impact of starvation of several amino acids on chlamydial devel-
opment (Coles et al., 1993; Pearce et al., 1994) and by Kahane
and her colleagues who tested heat shock (Kahane and Friedman,
1992). Abnormally enlarged RBs similar to those observed by
these groups had in fact been observed before. Over two decades
earlier, Akira Matsumoto had published electron micrographs
documenting the dramatic impact of penicillin on C. psittaci
and C. trachomatis development (Matsumoto and Manire, 1970;
Matsumoto, 1988). Similar to heat shock and tryptophan deple-
tion, penicillin caused the formation of abnormally enlarged
RBs that could be maintained in culture for as long as the host
cells were maintained healthy, and that could revert to normal
development to infectious EBs upon removal of the drug.
The common denominator of the early reports on chlamy-
dial persistence/recurrence is the observed ability of a chlamydia
growing in a cultured cell to withstand a variety of stresses by
entering into a non-septating phase for a period of time, from
which it can exit and revert to normal development upon removal
of the stressor. The formation of abnormally enlarged, mult-
inucleated (Lambden et al., 2006) aberrant RBs1 (aRBs) may
parallel stress-induced non-dividing filamentous forms in other
bacterial species that unlike Chlamydia are constrained by a rod-
shaped peptidoglycan sacculus (e.g., Escherichia coli, Bacillus sub-
tilis). Other stressors that cause multiple Chlamydia spp. growing
in vitro to produce aRBs have been described since. These include
chlamydiaphage superinfection of Chlamydia caviae (Hsia et al.,
2000), co-infection with viruses (Deka et al., 2006; Borel et al.,
2010) or protozoa (Romano et al., 2012, 2013), growth of
C. trachomatis in monocytes (Koehler et al., 1997), macrophage-
like (Nettelnbreker et al., 1998), or fibroblast-like synovial cells
(Hanada et al., 2003), iron restriction of C. trachomatis (Raulston,
1997), and exposure to a variety of antibiotics (Gieffers et al.,
2004). These forms have also been observed in vivo in varied
1Herein referred to as aberrant RBs or aRBs; although these have been variably
named aberrant bodies (ABs), or persistent bodies (PBs), this should be dis-
couraged as it convey that these forms have uniform properties acrossmultiple
stressors.
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contexts that may or may not relate to a persistent chlamydial
infection (Borel et al., 2008; Pospischil et al., 2009; Rank et al.,
2011; Phillips Campbell et al., 2012).
In the battleground that is an infection site, it is predictable
that both the pathogen and the infected host are experiencing
stress. Thus, chlamydiae undergoing a stress response should pre-
dictably appear during infection irrespective of whether the infec-
tion is acute or persistent. Indeed, aRBs can even be observed,
albeit infrequently, in in vitro culture in the absence of any
apparent stress (Tan et al., 2010). Moreover, the published lit-
erature is uneven in reporting the occurrence of typical, highly
enlarged aRBs in association with stress-induced in vitro per-
sistence/recurrence. In some reports, “aberrant inclusions” are
referred to, confusingly implying they contain aRBs or other
aberrant forms (e.g., miniature RBs), or that the inclusions
themselves are aberrant (e.g., smaller vs. larger than normal).
When found, the aRBs may also differ in their general appear-
ance (e.g., Variable vacuolation). An interesting case may be that
of C. trachomatis serovar L2 strains whereby in some stress-
induced persistence systems, typical, highly enlarged aRBs are
readily observed (Matsumoto, 1988; Coles et al., 1993; Harper
et al., 2000; Lambden et al., 2006; Capmany and Damiani,
2010; McKuen et al., 2013) while they are not readily appar-
ent in others (Rothermel et al., 1983; Shemer and Sarov, 1985;
Huston et al., 2008; Skilton et al., 2009). While such differences
may reflect experimental discrepancies or systematic differences,
they globally reflect that a putative stress response-based per-
sistence phenotype is unlikely to adhere to a single operational
mode as highlighted previously byWyrick (2010). Taken together,
the molecular, cellular, and mechanistic diversity of the stress
response in different Chlamydia strains, serovars and species
growing in different cells, and the parallel diversity of conditions,
which in different cells and sites of the infected host, can lead
to chlamydial stress, signify that the observation of aRBs in an
infected site is not sufficient to define a persistent infection. The
observation that the requirements of the persistence/recurrence
pathway can be fulfilled without the production of aRBs also sup-
ports that these forms are not necessary for persistence to occur.
Whether the stress response is involved in clinically observable
persistence is an open question for which the model systems have
not provided an answer as of yet. What is persistence? Without a
clear answer to this question, it is even more difficult to answer
the question of how it should be referred to. Without going into
the uncertainties on persistent C. trachomatis genital infection in
humans (i.e., recurrence from a persistent state vs. re-infection
from an infected partner), an answer to this question may be pro-
vided by expanding our field of vision beyond C. trachomatis, to
the veterinary Chlamydia species. All veterinary Chlamydia spp.,
including the phylogenetically close relatives of C. trachomatis,
Chlamydia muridarum, and Chlamydia suis that infect mice and
pigs, respectively, are first and foremost residents of the diges-
tive tract of their host. C. muridarum is used experimentally to
reproduce a genital infection in the mouse that replicates many
features of the human C. trachomatis infection (Rank, 1994),
but is not known to cause disease in wild mice. All veterinary
Chlamydia spp. are transmitted primarily via the oral-fecal route
and are thought to only cause disease in special circumstances,
for instance if the innate or immune defenses of a given ani-
mal are weakened, or because the nearby animal population is
highly infected such that individual animals are constantly re-
exposed to infectious chlamydiae (e.g., abortion “storms” caused
by Chlamydia abortus Pospischil et al., 2002). A possible expla-
nation for the relative inattention to the possibility of an enteric
phase for C. trachomatis may, therefore, relate to human evo-
lution, which has witnessed a continuous reduction in the role
of the fecal-oral route of transmission in the dissemination of
infectious diseases in human communities. Recent studies in the
mouse: C. muridarum model by Yeruva, Rank and colleagues
have demonstrated the ability of C. muridarum to persist in the
gastrointestinal (GI) tract of mice after oral inoculation (Yeruva
et al., 2013b). These authors have further shown that the first-line
antibiotic, azithromycin, while effective at clearing genital infec-
tion, was ineffective at clearing the GI infection (Yeruva et al.,
2013a). Jones and colleagues first alluded to the idea that C. tra-
chomatis may survive passage through the digestive tract and
colonize the lower digestive tract. They observed a correlation
between positive pharyngeal and rectal cultures in women who
reported no history of rectal intercourse (Jones et al., 1985). These
authors also observed a strong association between genital and
rectal infection in these women and proposed that “autoinocula-
tion with infected genital secretions may be the primary mecha-
nism by which such [rectal] infections are acquired.” In contrast,
Yeruva and Rank now propose that, in fact, autoinoculation may
be going in the reverse direction, i.e., from the infected GI tract to
the female genitalia (Rank and Yeruva, 2014). A sobering thought
then is that the practice of oral sex, which is on the rise par-
ticularly in adolescent populations where chlamydial infections
are also increasing, is providing the inoculum for a reservoir
of C. trachomatis persisting in the GI tract of humans, thereby
compensating for the loss of the fecal-oral route. The model pro-
posed by Yeruva and Rank is remarkable in its simplicity and
is consistent with well-known immune down-regulation mecha-
nisms that maintain the gut microbiota and exclude pathogens.
Occasional release of infectious EBs from a protected GI site
and consequent autoinoculation of the genital tract would also
explain the long periods of clinical “invisibility” some individuals
experience.
I was asked by the editors of this special issue to attempt to
provide new definitions for what Chlamydia researchers globally
refer to as persistence. Clearly this is not possible without a bet-
ter understanding of what persistence actually is. The possibility
of an enteric phase for C. trachomatis, highlighted by the work
of Yeruva and Rank, suggests that a colonization pathway to per-
sistence I alluded to initially, whereby C. trachomatis is primarily
a commensal of the GI tract that can occasionally cause disease
when in the wrong place, should be seriously evaluated. Whether
or not we continue to use, misuse, and abuse the word persistence
in chlamydial biology may depend on it.
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